Risk-based and diagnostics-linked personalized medicine for cancer

Authors: Srivastava, Sudhir1; Wagner, Paul D

Source: Personalized Medicine, Volume 4, Number 1, February 2007 , pp. 33-43(11)

Publisher: Future Medicine

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Personalized medicine is gaining momentum in healthcare by allowing physicians to determine an individual's predisposition to different diseases and to better diagnose and treat those diseases. Personalized medicine is frequently described as the right drug for the right patient at the right time; that is, a physician will prescribe treatment based on the individual characteristics of each patient such that the patient is likely to respond to a particular treatment with minimal adverse events. The heterogeneity of cancer makes the implementation of personalized medicine a necessity.

Keywords: biomarkers; cancer; oncogenes; raloxifene; risk assessment; tamoxifen; tumor suppressor genes

Document Type: Research article

DOI: 10.2217/17410541.4.1.33

Affiliations: 1: 1Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 6130 Executive Boulevard, Suite 3142, Rockville, MD 20892, USA., Email: ss1a@nih.gov

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$73.00 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A